Uncover DNA damage and repair-related gene signature and risk score model for glioma

References

• Cavaliere R, Lopes MBS, Schiff D. Low-grade gliomas: an update on pathology and therapy. The Lancet Neurol. 2005;4(11):1–14.
   PubMed Web of Science ®Google Scholar
• Yang K, Wu Z, Zhang H, et al. Glioma targeted therapy: insight into future of molecular approaches. Mol Cancer. 2022;21(1):1–32.
   PubMed Web of Science ®Google Scholar
• Elmore KB, Schaff LR. DNA repair mechanisms and therapeutic targets in glioma. Curr Oncol Rep. 2021;23(8):1–9.
   Web of Science ®Google Scholar
• Wang G, Zhou H, Tian L, et al. A prognostic DNA damage repair genes signature and its impact on immune cell infiltration in glioma. Front Oncol. 2021;11:682932.
   PubMedGoogle Scholar
• Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016;16(1):20–33.
   PubMed Web of Science ®Google Scholar
• Scarbrough PM, Weber RP, Iversen ES, et al. A cross-cancer genetic association analysis of the DNA repair and DNA damage signaling pathways for lung, ovary, prostate, breast, and colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2016;25(1):193–200.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495–501.
   PubMed Web of Science ®Google Scholar
• Hu Y, Guo M. Synthetic lethality strategies: beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci. 2020;111(9):3111–3121.
   PubMed Web of Science ®Google Scholar
• Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–637.
   PubMed Web of Science ®Google Scholar
• Meng X, Duan C, Pang H, et al. DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma. EBioMedicine. 2019;41:185–199.
   PubMed Web of Science ®Google Scholar
• Mouw KW, Goldberg MS, Konstantinopoulos PA, et al. DNA damage and repair biomarkers of immunotherapy responseDNA repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675–693.
   PubMed Web of Science ®Google Scholar
• Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15(11):669–682.
   PubMed Web of Science ®Google Scholar
• Li G, Li L, Li Y, et al. An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. Brain. 2022;145(3):1151–1161.
   PubMed Web of Science ®Google Scholar
• Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239–254. e236.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47-e47.
   Web of Science ®Google Scholar
• Li S, Han F, Qi N, et al. Determination of a six-gene prognostic model for cervical cancer based on WGCNA combined with LASSO and Cox-PH analysis. World J Surg Onc. 2021;19(1):1–11.
   PubMed Web of Science ®Google Scholar
• Kassambara A, Kosinski M, Biecek P, et al. Package ‘survminer’. Drawing survival curves using ‘ggplot2. R Package Version 03 1. 2017. https://cran.r-project.org/web/packages/survminer/index.html
   Google Scholar
• Blanche P, Blanche MP. 2019. Package ‘timeROC’. https://cran.r-project.org/web/packages/timeROC/index.html
   Google Scholar
• Mayakonda A, Lin D-C, Assenov Y, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756.
   PubMed Web of Science ®Google Scholar
• Huang X, Hu H, Liu J, et al. Immune analysis and small molecule drug prediction of hepatocellular carcinoma based on single sample gene set enrichment analysis. Cell Biochem Biophys. 2022;80(2):427–434.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262.
   PubMed Web of Science ®Google Scholar
• Maeser D, Gruener RF, Huang RS. OncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang S, Bai H, et al. Identification of five glycolysis-related gene signature and risk score model for colorectal cancer. Front Oncol. 2021;11:588811.
   PubMed Web of Science ®Google Scholar
• Leal-Esteban LC, Fajas L. Cell cycle regulators in cancer cell metabolism. et. Biochim Biophys Acta Mol Basis Dis. 2020;1866(5):165715.
   PubMed Web of Science ®Google Scholar
• Goel S, DeCristo MJ, McAllister SS, et al. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28(11):911–925.
   PubMed Web of Science ®Google Scholar
• Molinaro AM, Taylor JW, Wiencke JK, et al. Genetic and molecular epidemiology of adult diffuse glioma. Nat Rev Neurol. 2019;15(7):405–417.
   PubMed Web of Science ®Google Scholar
• Kuan AS, Green J, Kitahara CM, et al. Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA. Neuro Oncol. 2019;21(7):944–952.
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Guner G, Rodriguez FJ, et al. Absence of cytomegalovirus in glioblastoma and other high-grade gliomas by real-time PCR, immunohistochemistry, and in situ hybridization absence of CMV in glioblastoma and other high-grade gliomas. Clin Cancer Res. 2017;23(12):3150–3157.
   PubMed Web of Science ®Google Scholar
• Adel Fahmideh M, Schwartzbaum J, Frumento P, et al. Association between DNA repair gene polymorphisms and risk of glioma: a systematic review and meta-analysis. Neuro Oncol. 2014;16(6):807–814.
   PubMed Web of Science ®Google Scholar
• Marchan R, Stewart JD, Lesjak M. EDI3, a key enzyme of choline metabolism controls tumour cell migration. EXCLI Journal. 2012;11:260.
   PubMed Web of Science ®Google Scholar
• Marchan R, Büttner B, Lambert J, et al. Glycerol-3-phosphate acyltransferase 1 promotes tumor cell migration and poor survival in ovarian carcinomaGPAM mediates tumor cell migration. Cancer Res. 2017;77(17):4589–4601.
   PubMed Web of Science ®Google Scholar
• Diao P-Y, Li S-X, Peng J, et al. Overexpression of EP300-interacting inhibitor of differentiation 3 predicts poor prognosis in patients with glioblastoma multiforme. Int J Clin Exp Pathol. 2020;13(5):979.
   PubMed Web of Science ®Google Scholar
• Choi M, Tennant SM, Simon R, et al. Progress towards the development of Klebsiella vaccines. Expert Rev Vaccines. 2019;18(7):681–691.
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang M, Gan H, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9(1):1–14.
   PubMedGoogle Scholar
• Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol. 2018;233(1):378–386.
   PubMed Web of Science ®Google Scholar
• Kuester D, Peng D, Ruemmele P, et al. Silencing of MGMT expression by promoter hypermethylation in the metaplasia–dysplasia–carcinoma sequence of Barrett’s esophagus. Cancer Lett. 2009;275(1):117–126.
   PubMed Web of Science ®Google Scholar
• Zekri A-RN, Bahnasy AA, Mohamed WS, et al. Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. J Adv Res. 2014;5(1):27–40.
   PubMedGoogle Scholar
• Mokhtar M, Kondo K, Namura T, et al. Methylation and expression profiles of MGMT gene in thymic epithelial tumors. Lung Cancer. 2014;83(2):279–287.
   PubMed Web of Science ®Google Scholar
• Wu S, Li X, Gao F, et al. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Neuro Oncol. 2021;23(6):920–931.
   PubMed Web of Science ®Google Scholar
• Prolla TA, Baker SM, Harris AC, et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet. 1998;18(3):276–279.
   PubMed Web of Science ®Google Scholar
• Tahara Y-K, Kietrys AM, Hebenbrock M, et al. Dual inhibitors of 8-oxoguanine surveillance by OGG1 and NUDT1. ACS Chem Biol. 2019;14(12):2606–2615.
   PubMed Web of Science ®Google Scholar
• Gad H, Koolmeister T, Jemth A-S, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP Pool. Nature. 2014;508(7495):215–221.
   PubMed Web of Science ®Google Scholar
• Huber KV, Salah E, Radic B, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014;508(7495):222–227.
   PubMed Web of Science ®Google Scholar
• Ellermann M, Eheim A, Rahm F, et al. Novel class of potent and cellularly active inhibitors devalidates MTH1 as broad-spectrum cancer target. ACS Chem Biol. 2017;12(8):1986–1992.
   PubMed Web of Science ®Google Scholar
• van der Waals LM, Laoukili J, Jongen JMJ, et al. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures. Sci Rep. 2019;9(1):819.
   PubMedGoogle Scholar
• Gubin MM, Artyomov MN, Mardis ER, et al. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–3421.
   PubMed Web of Science ®Google Scholar
• Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
   PubMed Web of Science ®Google Scholar